| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Finance & Corp Controller | SVP, Corporate Controller | VP, Corporate Controller
1 company
Timothy J. Sangiovanni is SVP, Finance & Corp Controller at ZVRA. Timothy J. Sangiovanni's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $304K at current prices.
Our model assigns Timothy J. Sangiovanni a below-average insider score of 49/100, based on 4 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +20.7%.
Net of sales, the ZVRA filings show accumulation of 11,450 shares.
Timothy J. Sangiovanni has 18 Form 4 filings on record from January 2018 to May 2026, all as SVP, Finance & Corp Controller at Zevra Therapeutics (ZVRA), 2018–2026.
The 27 reported transactions were 12 option or other derivative awards, 9 open-market purchases, 3 open-market sales and 3 option exercises.
Counted by filing, the open-market trades come to 5 purchases worth about $18K and 3 sales worth about $67K.
The largest open-market purchase was 3,000 shares of ZVRA at an average $2.52 on October 12, 2018, about $8K.
The largest open-market sale was 3,000 shares of ZVRA at an average $9.18 on February 3, 2026, about $28K.
All 3 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | ZVRA Zevra Therapeutics, Inc. | SVP, Finance & Corp Controller | Sell10b5-1 | 3,000 | $9.18 | $27,548.10 | -9.2% | +9.7% | - | |
| Jan 30, 2026 | ZVRA Zevra Therapeutics, Inc. | SVP, Finance & Corp Controller | Sale+OE10b5-1 | 1,750 | $8.82 | $15,442.00 | -7.7% | +13.0% | - | |
| Feb 13, 2025 | ZVRA Zevra Therapeutics, Inc. | SVP, Finance & Corp Controller | Sell10b5-1 | 3,000 | $7.86 | $23,587.80 | -15.5% | +1.9% | +6.4% | |
| Mar 10, 2023 | ZVRA Zevra Therapeutics, Inc. | SVP, Corporate Controller | Buy | 1,200 | $4.14 | $4,967.17 | +36.9% | +33.9% | +47.7% | |
| Mar 13, 2020 | ZVRA Zevra Therapeutics, Inc. | VP, Corporate Controller | Buy | 4,000 | $0.20 | $800.00 | +28.6% | - | - | |
| Mar 10, 2020 | ZVRA Zevra Therapeutics, Inc. | VP, Corporate Controller | Buy | 8,000 | $0.25 | $2,038.31 | +133.3% | - | - | |
| Sep 24, 2019 | ZVRA Zevra Therapeutics, Inc. | VP, Corporate Controller | Buy | 3,000 | $0.74 | $2,220.00 | +100.0% | - | - | |
| Oct 12, 2018 | ZVRA Zevra Therapeutics, Inc. | VP, Corporate Controller | Buy | 3,000 | $2.53 | $7,575.00 | New | - | - |